Prostate Cancer (Diagnosis), Quality of Life, Reliability, UCLA Prostate Cancer Index, Validity
Conditions
Brief summary
This study will evaluate the cross-cultural adaptation, validity, and reliability of the Turkish version of the UCLA Prostate Cancer Index in men diagnosed with prostate cancer. The original instrument will be translated and culturally adapted following standardized procedures. The psychometric properties of the Turkish version will be examined in patients attending routine follow-up visits at a urology clinic. Internal consistency will be assessed using Cronbach's alpha coefficients, and test-retest reliability will be evaluated using intraclass correlation coefficients (ICC) in a subset of participants. Measurement error will be determined by calculating the standard error of measurement (SEM) and the smallest real difference at the 95% confidence level (SRD95). Construct validity will be examined through exploratory factor analysis, and convergent validity will be assessed by testing predefined hypotheses regarding correlations between the UCLA Prostate Cancer Index and established quality-of-life instruments (SF-36 and EORTC QLQ-PR25). The findings are expected to provide a reliable and valid prostate cancer-specific quality-of-life assessment tool for use in Turkish-speaking populations.
Interventions
OTHERQuestionnaires
Participants will complete the Turkish version of the UCLA Prostate Cancer Index along with the SF-36 and EORTC QLQ-PR25 questionnaires. No intervention will be applied.
Sponsors
Lokman Hekim University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
* Male patients * Diagnosis of prostate cancer
Exclusion criteria
* Severe psychiatric or mental disorders that may impair the ability to complete the questionnaires properly * Presence of congenital deformities
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| UCLA Prostate Cancer Index | 1 hour | The University of California, Los Angeles (UCLA) Prostate Cancer Index was developed in English in 1998 by Litwin et al. and has been psychometrically validated in prostate cancer populations. It evaluates urinary, sexual, and bowel function and the associated symptom-related bother in men treated for prostate cancer |
| EORTC QLQ-PR25 | 1 hour | The EORTC QLQ-PR25 is a prostate cancer-specific module consisting of 25 items and comprising six symptom subdomains: urinary symptoms, incontinence aid, bowel symptoms, hormonal treatment-related symptoms, sexual activity, and sexual functioning |
| SF-36 | 1 hour | It is a widely used 36-item questionnaire that evaluates health-related QoL across eight domains, including physical functioning, role limitations due to physical and emotional problems, mental health, vitality, social functioning, bodily pain, and general health |
Countries
Turkey (Türkiye)
Outcome results
None listed